Clofibric Acid

"Clofibric Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.

Descriptor ID

D002995

MeSH Number(s)

D02.241.081.160.700.500.500

D02.355.726.305.500

D02.755.654.305.500

Concept/Terms

Clofibric Acid

p-Chlorophenoxyisobutyrate

NSC-1149

Below are MeSH descriptors whose meaning is more general than "Clofibric Acid".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Carboxylic Acids [D02.241]
Acids, Acyclic [D02.241.081]
Butyric Acids [D02.241.081.160]
Isobutyric Acids [D02.241.081.160.700]
Fibric Acids [D02.241.081.160.700.500]
Clofibric Acid [D02.241.081.160.700.500.500]
Ethers [D02.355]
Phenyl Ethers [D02.355.726]
Fibric Acids [D02.355.726.305]
Clofibric Acid [D02.355.726.305.500]
Phenols [D02.755]
Phenyl Ethers [D02.755.654]
Fibric Acids [D02.755.654.305]
Clofibric Acid [D02.755.654.305.500]

Below are MeSH descriptors whose meaning is related to "Clofibric Acid".

Below are MeSH descriptors whose meaning is more specific than "Clofibric Acid".

Clofibric Acid
Clofibrate

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Clofibric Acid" by people in Harvard Catalyst Profiles by year, and whether "Clofibric Acid" was a major or minor topic of these publication.

Bar chart showing 6 publications over 5 distinct years, with a maximum of 2 publications in 2007

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	0	1	1
2004	1	0	1
2006	0	1	1
2007	1	1	2
2008	0	1	1

Below are the most recent publications written about "Clofibric Acid" by people in Profiles.

Novel targets that affect high-density lipoprotein metabolism: the next frontier. Am J Cardiol. 2009 Nov 16; 104(10 Suppl):52E-7E.

View in: PubMed
The effects of medications used for the management of dyslipidemia on postprandial lipemia. Curr Med Chem. 2009; 16(2):203-17.

View in: PubMed
Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clin Endocrinol (Oxf). 2009 Jun; 70(6):815-28.

View in: PubMed
High-density lipoprotein metabolism: potential therapeutic targets. Am J Cardiol. 2007 Dec 03; 100(11 A):n32-40.

View in: PubMed
Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI. J Lipid Res. 2007 Aug; 48(8):1832-45.

View in: PubMed
The acyl-CoA thioesterase I is regulated by PPARalpha and HNF4alpha via a distal response element in the promoter. J Lipid Res. 2007 Aug; 48(8):1781-91.

View in: PubMed
[IV Brazilian Guideline for Dyslipidemia and Atherosclerosis prevention: Department of Atherosclerosis of Brazilian Society of Cardiology]. Arq Bras Cardiol. 2007 Apr; 88 Suppl 1:2-19.

View in: PubMed
Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. J Clin Epidemiol. 2007 Aug; 60(8):812-8.

View in: PubMed
Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy. 2007 Mar; 27(3):325-32.

View in: PubMed
Safety considerations with fibrate therapy. Am J Cardiol. 2007 Mar 19; 99(6A):3C-18C.

View in: PubMed

Related Networks

People

Explore

Similar Concepts

Top Journals

Am J Cardiol
JAMA
J Clin Epidemiol
Expert Opin Drug Saf
Cancer Lett
J Lipid Res
Clin Endocrinol (Oxf)
Arq Bras Cardiol
Am J Pathol
AIDS Care